

Patent Application
Attorney Docket No. PC25420A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents P. O. Box 1450, Alexandria, VA 22313-1450 on this 11th day of May 2004

By

Irene Grantlam

(Signature of person mailing)

Irene Grantlam

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Charlotte Moria Norfor :
Allerton, et al.

APPLICATION NO.: 10/727,168 : Examiner: To Be Assigned

FILING DATE: December 2, 2003 : Group Art Unit: To Be Assigned

TITLE: MORPHOLINE DOPAMINE AGONISTS :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.



It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: May 10, 2004
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

Respectfully submitted,

Martha G. Munchhof
Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47, 811



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25420A	SERIAL NO. 10/727,168
	APPLICANT Charlotte Moria Norfor Allerton, et al.	
	FILING DATE December 2, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	2	5	0	3	0	5	9	4/4/50	Miescher, et al.	260	309.6	
	US	2	5	9	9	0	0	0	6/3/52	Kerwin, et al.	260	570.7	
	US	3	3	8	1	0	0	9	4/30/68	Palazzo, et al.	260	268	
	US	3	5	1	1	8	3	6	5/12/70	Hess	260	256.4	
	US	3	5	2	7	7	6	1	9/8/70	Archibald, et al.	260	293	
	US	3	9	9	7	6	6	6	12/14/76	Witte, et al.	424	250	
	US	4	0	2	6	8	9	4	5/31/77	Winn, et al.	260	256.4Q	
	US	4	1	8	8	3	9	0	2/12/80	Campbell	424	251	
	US	4	2	5	2	7	2	1	2/24/81	Silvestrini, et al.	260	243.3	
	US	4	3	1	5	0	0	7	2/9/82	Manoury	424	251	
	US	4	7	0	3	0	6	3	10/27/87	Imai, et al.	514	603	
	US	5	5	7	6	3	2	2	11/19/96	Takase, et al.	514	260	
	US	5	6	9	8	5	6	0	12/16/97	Onoda, et al.	514	267	
	US	6	0	3	7	3	4	6	3/14/00	Doherty, et al.	514	258	
	US	6	2	9	7	3	8	2	10/2/01	Scott	546	276.4	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	9	1	1	1	1	7	2	8/8/91	PCT	A61K	9/00		
	WO	9	3	0	6	1	0	4	4/1/93	PCT	C07D	487/04		
	WO	9	3	0	7	1	4	9	4/15/93	PCT	C07D	487/04		
	WO	9	3	1	2	0	9	5	6/24/93	PCT	C07D	239/91		
	WO	9	4	0	0	4	5	3	1/6/94	PCT	C07D	473/30		
	WO	9	4	0	2	5	1	8	2/3/94	PCT	C08B	37/16		
	WO	9	4	0	5	6	6	1	3/17/94	PCT	C07D	471/04		
	WO	9	5	1	9	9	7	8	7/27/95	PCT	C07D	471/14		
	WO	9	6	2	1	6	5	6	7/18/96	PCT	C07D	295/08		

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>						ATTY. DOCKET NO. PC25420A				SERIAL NO. 10/727,168				
						APPLICANT Charlotte Moria Norfor Allerton, et al.								
						FILING DATE December 2, 2003				GROUP To Be Assigned				
	WO	9	8	4	9	1	6	6	11/5/98	PCT	C07D	487/04		
	WO	9	8	5	5	1	4	8	12/10/98	PCT	A61K	47/48		
	WO	9	9	0	2	1	5	9	1/21/99	PCT	A61K	31/495		
	WO	9	9	2	4	4	3	3	5/20/99	PCT	C07D	487/04		
	WO	9	9	3	0	6	9	7	6/24/99	PCT	A61K	31/00		
	WO	9	9	3	2	4	7	5	7/1/99	PCT	C07D	311/58		
	WO	9	9	5	4	3	3	3	10/28/99	PCT	C07D	487/04		
	WO	9	9	5	4	3	5	8	10/28/99	PCT	C07K	14/68		
	WO	9	9	5	5	6	7	9	11/4/99	PCT	C07D	217/04		
	WO	9	9	6	4	0	0	2	12/16/99	PCT	A61K	31/47		
	WO	9	9	6	4	0	0	8	12/16/99	PCT	A61K	31/535		
	WO	0	0	0	2	5	5	0	1/20/00	PCT	A61K	31/00		
	WO	0	0	1	2	0	7	5	3/9/00	PCT	A61K	31/13		
	WO	0	0	2	4	7	4	5	5/4/00	PCT	C07D	487/04		
	WO	0	0	2	8	9	9	3	5/25/00	PCT	A61K	31/495		
	WO	0	0	3	3	8	2	5	6/15/00	PCT	A61K	31/00		
	WO	0	0	5	8	3	6	1	10/5/00	PCT	C07K	14/68		
	WO	0	0	7	4	6	7	9	12/14/00	PCT	A61K	31/445		
	WO	0	1	0	5	4	0	1	1/25/01	PCT	A61K	31/4184		
	WO	0	1	1	3	1	1	2	2/22/01	PCT	G01N	33/53		
	WO	0	1	1	4	8	7	9	3/1/01	PCT	G01N	33/53		
	WO	0	1	2	7	1	1	2	4/19/01	PCT	C07D	487/04		
	WO	0	1	2	7	1	1	3	4/19/01	PCT	C07D	487/04		
	EP	0	4	6	3	7	5	6	1/2/92	EP	C07D	487/04		
	EP	0	5	2	6	0	0	4	7/2/92	EP	C07D	487/04		
	EP	0	9	9	5	7	5	0	4/26/00	EP	C07D	487/04		
	EP	0	9	9	5	7	5	1	4/26/00	EP	C07D	487/04		
	EP	1	0	9	2	7	1	8	4/18/01	EP	C07D	473/30		
	EP	1	0	9	2	7	1	9	4/18/01	EP	C07D	487/04		

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC25420A	SERIAL NO. 10/727,168
APPLICANT Charlotte Moria Norfor Allerton, et al.		FILING DATE December 2, 2003	
GROUP To Be Assigned			

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
			Berman, et al., "Femal Sexual Dysfunction: Incidence, Pahtophysiology, Evaluation, and Treatment Options", <u>Urology</u> 54, pp. 385-391 (1999)
			Melman, et al., "The Epidemiology and Pathophysiology of Erectile Dysfunction", <u>The Journal of Urology</u> 161, pp. 5-11 (1999)
			Gonzalez, et al., "[³ H]7-OH-DPAT is Capable of Labeling Dopamine D ₂ as well as D ₃ Receptors", <u>European Journal of Pharmacology</u> 272, pp. R1-R3 (1995)
			Ballard, et al., "Effects of Sildenafil on the Relaxation of Human Corpus Cavenosum Tissue in Vitro and on the Activities of cyclic Nucleotide Phosphodiesterase Isozymes", <u>The Journal of Urology</u> 159(6), pp. 2164-2171 (1998)
			Rotella, et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction", <u>J. Med. Chem.</u> , 43, pp. 1257-1263 (2000)
			Berge, et al., "Pharmaceutical Salts", <u>Journal of Pharmaceutical Sciences</u> 66(1), pp. 1-19 (1977)
			Taub, et al., "Relationship between Contraction and Relaxation in Human and Rabbit Corpus Cavernosum", <u>Urology</u> 42(6), pp. 698-704 (1993)
			Leiblum, "Definition and Classification of Female Secual Disorders", <u>International Journal of Impotence Research</u> 10(Suppl. 2), pp. S104-S106 (1998)
			Goldstein, et al., "Vasculogenic Female Sexual Dysfunction: Vaginal Engorgement and Clitoral Erectile Insufficiency Syndromes", <u>International Journal of Impotence Research</u> 10(Suppl. 2), pp. S84-S90 (1998)
			Park, et al., "Vasculogenic Female Sexual Dysfunction: The Hemodynamic Basis for Vaginal Engorgement Insufficiency and Clitoral Erectile Insufficiency", <u>International Journal of Impotence Research</u> 9, pp. 27-37 (1997)
			Levin, "VIP, Vagina, Clitoral and Periurethral Glans – an Update on Human Female Genital Arousal", <u>Exp. Clin. Endocrinol.</u> 98(2), pp. 61-69 (1991)
			Lerner, et al., "A Review of Erectile Dysfunction: New Insights and More Questions", <u>The Journal of Urology</u> 149, pp. 1246-1255 (1993)
			Feldman, et al., "Impotence and its Medical and Psychosocial Correlates: Resulst of the Massachusetts Male Aging Study", <u>The Journal of Urology</u> 151, pp. 54-61 (1994)
			Naylor, "Endogenous Neurotransmitters Mediating Penile Erection", <u>British Journal of Urology</u> 81, pp. 424-431 (1998)
			Carrier, et al., "Erectile Dysfunction", <u>Clinical Andrology</u> 23(4), pp. 773-782 (1994)

EXAMINER	DATE CONSIDERED
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	